Hasan TEZER, Ceyda TUNA KIRSAÇLIOĞLU, Saliha KANIK YÜKSEK, Aslı Nur ÖZKAYA PARLAKAY, Belgin GÜLHAN

Cytomegalovirus hepatitis in 49 pediatric patients with normal immunity

Background/aim: Cytomegalovirus (CMV) hepatitis is generally asymptomatic or rarely can lead to severe complications in immunocompetent hosts. This study aims to evaluate CMV hepatitis in immunocompetent young children, which is discussed relatively rarely in the literature. Materials and methods: A retrospective review of 49 pediatric patients with CMV hepatitis from January 2005 to December 2010 was performed. Results: The median age of the patients was 5.81 ± 6.49 months and 57.1% were female. Complaints were prolonged jaundice, vomiting, diarrhea, and abdominal distension. Seventeen patients (34.6%) had congenital or probable congenital CMV infection, while 32/49 (65.3%) had perinatal CMV infection. CMV hepatitis was accompanied by other system findings in 22 patients (44.9%), and only liver involvement was present in 27/49 (55.1%). Alanine aminotransferase and aspartate aminotransferase were elevated together in all patients. Cholestatic hepatitis was present in 13 patients (26.5%). Four patients (8.16%) were treated with ganciclovir. Complete improvement of hepatitis occurred in 48/49 (97.95%). The recovery time of liver function tests was 7 180 days (mean: 53.92 ± 40.8). Conclusion: CMV hepatitis is usually mild and has a good outcome in immunocompetent individuals. However, cases should be carefully evaluated due to the important role of CMV in the etiology of infantile and neonatal hepatitis.

PDF

___

1. Horwitz CA, Henle W, Henle G, Snover D, Rudnick H, Balfour HH Jr, Mazur MH, Watson R, Schwartz B, Muller N. Clinical and laboratory evaluation of cytomegalovirus-induced mononucleosis in previously healthy individuals. Report of 82 cases. Medicine (Baltimore) 1986; 65: 124-134.
2. Tezer H, Seçmeer G,Kara A, Ceyhan M, Cengiz AB, Devrim İ, Us D, Yüce A, Gürakan F, Yıldırım İ et al. Cytomegalovirus hepatitis and ganciclovir treatment in immunocompetent children. Turk J Pediatr 2008; 50: 228-234.
3. Zuppan CW, Bui HD, Grill BG. Diffuse hepatic fibrosis in congenital cytomegalovirus infection. J Pediatr Gastroenterol Nutr 1986; 5: 489-491.
4. Fischler B, Ehrnst A, Forsgren M, Orvell C, Nemeth A. The viral association of neonatal cholestasis in Sweden: a possible link between cytomegalovirus infection and extrahepatic biliary atresia. J Pediatr Gastroenterol Nutr 1998; 27: 57-64.
5. Eddleston M, Peacock S, Juniper M, Warrell DA. Severe cytomegalovirus infection in immunocompetent patient. Clin Infect Dis 1997; 24: 52-56.
6. American Academy of Pediatrics. Cytomegalovirus infection. In: Pickering LK, Baker CJ, Long SS, McMillian JA, editors. Red Book: 2009 Report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village, IL, USA: American Academy of Pediatrics; 2009. pp. 708-709.
7. Rafailidis PI,Mourtzoukou EG,Varbobitis IC, Falagas ME. Severe cytomegalovirus infection in apparently immunocompetent patients: a systematic review. Virol J 2008; 5: 47.
8. Vancíková Z, Dvorák P. Cytomegalovirus infection in immunocompetent and immunocompromised individualsa review. Curr Drug Targets Immune Endocr Metabol Disord 2001; 1: 179-187.
9. Hadaya K, Kaiser L, Rubbia-Brandt L, Gervaix A, Diana A. Ganciclovir for severe cytomegalovirus primary infection in an immunocompetent child. Eur J Clin Microbiol Infect Dis 2004; 23: 218-220.
10. Just-Nübling G, Korn S, Ludwig B, Stephan C, Doerr HW, Preiser W. Primary cytomegalovirus infection in an outpatient setting laboratory markers and clinical aspects. Infection 2003; 31: 318- 323.
11. Zubiaurre L, Zapata E, Bujanda L, Castillo M, Oyarzabal I, Gutiérrez-Stampa MA, Cosme A. Cytomegalovirus hepatitis and myopericarditis. World J Gastroenterol 2007; 13: 647-648.
12. White FV, Dehner LP. Viral diseases of the liver in children: diagnostic and differential diagnostic considerations. Pediatr Dev Pathol 2004: 7; 552-567.
13. Vancíková Z, Kucerová T, Pelikán L, Zikmundová L, Priglová M. Perinatal cytomegalovirus hepatitis: to treat or not to treat with ganciclovir. J Paediatr Child Health 2004; 40: 444-448.
14. Nigro G, Krzysztofiak A, Bartmann U, Clerico A, Properzi E, Valia S, Castello M. Ganciclovir therapy for cytomegalovirus-associated liver disease in immunocompetent or immunocompromised children. Arch Virol 1997; 142: 573-580.
15. Tajiri H, Kozaiwa K, Tanaka-Taya K, Tada K, Takeshima T, Yamanishi K, Okada S. Cytomegalovirus hepatitis confirmed by in situ hybridization in 3 immunocompetent infants. Scand J Infect Dis 2001; 33: 790-793.
16. Kimberlin DW. Antiviral therapy for cytomegalovirus infections in pediatric patients. Semin Pediatr Infect Dis J 2006; 13: 22-30.
17. Pass RF. Cytomegalovirus. In: Long SS, Pickering LK, Prober CG, editors. Principles and Practice of Pediatric Infectious Diseases. Philadelphia, PA, USA: Churchill Livingstone; 2008. pp. 1029- 1035.
18. Doan TT, Phung TT, Pham HV, Pham SH, Nguyen LT. Effect of ganciclovir for the treatment of severe cytomegalovirusassociated pneumonia in children without a specific immunocompromised state. BMC Infect Dis 2013; 13: 424.
19. Plosa EJ, Esbenshade JC, Fuller MP, Weitkamp JH. Cytomegalovirus infection. Pediatr Rev 2012; 33: 156-163.
20. Stagno S. Cytomegalovirus. In: Kliegman RM, Stanton B, Geme S, Schor N, Behrman RE, editors. Nelson Textbook of Pediatrics. 19th ed. Philadelphia, PA, USA: WB Saunders; 2010. pp. 1115- 1117.
21. Kumar A, Herbein G. Epigenetic regulation of human cytomegalovirus latency: an update. Epigenomics 2014; 6: 533- 546.
22. Kano Y, Shiohara T. Current understanding of cytomegalovirus infection in immunocompetent individuals. J Dermatol Sci 2000; 22: 196-204.
23. Limaye AP, Kirby KA, Rubenfeld GD, Leisenring WM, Bulger EM, Neff MJ, Gibran NS, Huang ML, Santo Hayes TK, Corey L et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 2008; 300: 413-422.
24. Cook CH, Trgovcich J. Cytomegalovirus reactivation in critically ill immunocompetent hosts: a decade of progress and remaining challenges. Antiviral Res 2011; 90: 151-159.
25. Bontant T, Sedlaçek P, Balduzzi A, Gaspar B, Cesaro S, Einsele H, Peters C, Dalle JH. Survey of CMV management in pediatric allogeneic HSCT programs, on behalf of the inborn errors, infectious diseases and pediatric diseases working parties of EBMT. Bone Marrow Transplant 2014; 49: 276-279.